Related Experiment Videos
How to target small cell lung cancer.
Gerhard Hamilton1, Barbara Rath1, Ernst Ulsperger1
1Ludwig Boltzmann Cluster of Translational Oncology, A-1090 Vienna, Austria.
Oncoscience
|October 2, 2015
Summary
Small cell lung cancer (SCLC) dissemination involves CHI3L1-positive circulating tumor cells (CTCs) that promote immune suppression. Targeting CHI3L1 may offer a new strategy to inhibit SCLC spread and drug resistance.
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- Small cell lung cancer (SCLC) is aggressive with poor outcomes.
- Mechanisms of SCLC metastasis and drug resistance remain unclear.
- Common SCLC genetic alterations (p53, Rb inactivation) complicate targeted therapy.
Purpose of the Study:
- Investigate novel targets for SCLC dissemination and drug resistance.
- Characterize the biology of SCLC circulating tumor cells (CTCs).
- Identify potential therapeutic strategies to inhibit SCLC progression.
Main Methods:
- Analysis of pure SCLC CTC cultures.
- Assessment of gene and protein expression in SCLC cells.
- Evaluation of CTC interactions with immune cells.
Main Results:
- Chitinase-3-like-1 (CHI3L1) expression identified in SCLC CTCs.
- CHI3L1 controls vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP9) expression.
- CHI3L1-positive CTCs promote M2 macrophage differentiation and PD-1 expression, suggesting immune suppression.
- SCLC cell conversion to invasive CHI3L1-positive CTCs linked to inflammatory cytokines.
Conclusions:
- SCLC dissemination is associated with conversion to invasive, immune-suppressive CHI3L1-positive CTCs.
- CHI3L1 is a potential therapeutic target to reduce SCLC cell spread.
- CHI3L1 may be relevant for other cancers like glioblastoma.